Veterinary Medicines

Alpramil 16 mg/40 mg film-coated tablets for cats weighing at least 4 kg

Authorised
  • Praziquantel
  • Milbemycin oxime
Download as PDF

Product identification

Medicine name:
ALPRAMIL (16+40) MG/TAB ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ
Alpramil 16 mg/40 mg film-coated tablets for cats weighing at least 4 kg
Active substance:
  • Praziquantel
  • Milbemycin oxime
Target species:
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Praziquantel
    40.00
    milligram(s)
    /
    1.00
    Tablet
  • Milbemycin oxime
    16.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:
  • Box with 25 PVC / PE / PVDC - Aluminium blisters each containing 2 tablets.
  • Box with 25 PVC / PE / PVDC - Aluminium blisters each containing 1 tablet.
  • Box with 10 PVC / PE / PVDC - Aluminium blisters each containing 1 tablet.
  • Box with 1 PVC / PE / PVDC - Aluminium blister containing 4 tablets.
  • Box with 25 PVC / PE / PVDC - Aluminium blisters each containing 4 tablets.
  • Box with 10 PVC / PE / PVDC - Aluminium blisters each containing 4 tablets.
  • Box with 10 PVC / PE / PVDC - Aluminium blisters each containing 2 tablets.
  • 1 box with 1PVC / PE / PVDC - Aluminium blister containing 2 tablets.
  • 1 box with 1PVC / PE / PVDC - Aluminium blister containing 1 tablet.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Alfasan Nederland B.V.
  • Lelypharma B.V.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 68697/27-06-2022/K-0248603
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0364/003
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 15/05/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 15/05/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."